Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer.

cancer related thrombosis circulating metastatic disease circulating tumor cell clusters circulating tumor cells circulating tumor emboli circulating tumor-associated cells

Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 06 2020
Historique:
received: 30 08 2019
revised: 13 11 2019
accepted: 25 11 2019
pubmed: 1 12 2019
medline: 9 3 2021
entrez: 1 12 2019
Statut: ppublish

Résumé

Circulating ensembles of tumor-associated cells (C-ETACs) which comprise tumor emboli, immune cells and fibroblasts pose well-recognized risks of thrombosis and aggressive metastasis. However, the detection, prevalence and characterization of C-ETACs have been impaired due to methodological difficulties. Our findings show extensive pan-cancer prevalence of C-ETACs on a hitherto unreported scale in cancer patients and virtual undetectability in asymptomatic individuals. Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples of 16,134 subjects including 5,509 patients with epithelial malignancies in various organs and 10,625 asymptomatic individuals with age related higher cancer risk. PBMCs were treated with stabilizing reagents to protect and harvest apoptosis-resistant C-ETACs, which are defined as cell clusters comprising at least three EpCAM

Identifiants

pubmed: 31785151
doi: 10.1002/ijc.32815
pmc: PMC7217040
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

3485-3494

Informations de copyright

© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

Breast Care (Basel). 2011;6(3):199-207
pubmed: 21779225
Ann Intern Med. 2011 Oct 18;155(8):481-92
pubmed: 22007042
Proc Natl Acad Sci U S A. 2016 May 3;113(18):4947-52
pubmed: 27091969
J Clin Pathol. 2005 Mar;58(3):308-12
pubmed: 15735166
Nat Rev Clin Oncol. 2017 Jan;14(1):32-44
pubmed: 27550857
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
J Pathol. 2012 Jan;226(2):380-93
pubmed: 21953325
Phys Biol. 2012 Feb;9(1):016005
pubmed: 22307026
Curr Opin Cell Biol. 2001 Oct;13(5):555-62
pubmed: 11544023
Clin Ther. 2018 Apr;40(4):526-534
pubmed: 29573852
Nat Rev Cancer. 2018 Apr;18(4):255-263
pubmed: 29376520
Biochim Biophys Acta. 2013 Dec;1833(12):3481-3498
pubmed: 23830918
Science. 2013 Sep 13;341(6151):1186-8
pubmed: 24031008
Nat Methods. 2015 Jul;12(7):685-91
pubmed: 25984697
Crit Rev Oncog. 2016;21(3-4):155-168
pubmed: 27915969
J Cancer Res Clin Oncol. 2014 Dec;140(12):2157-62
pubmed: 25028119
Cancers (Basel). 2011 Jun 08;3(2):2540-53
pubmed: 24212822
Clin Chem. 2016 Mar;62(3):505-13
pubmed: 26861552
Sci Rep. 2018 Oct 12;8(1):15218
pubmed: 30315187
J Pathol. 2009 Nov;219(3):287-93
pubmed: 19731255
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Front Immunol. 2017 Sep 13;8:1106
pubmed: 28955335
Transl Lung Cancer Res. 2017 Aug;6(4):418-430
pubmed: 28904886
BMC Cancer. 2014 Mar 28;14:226
pubmed: 24674711
J Med Screen. 2018 Jun;25(2):110-112
pubmed: 28929865
PLoS One. 2012;7(7):e41942
pubmed: 22848668
Ann Intern Med. 2016 Feb 16;164(4):244-55
pubmed: 26756588
Mol Oncol. 2017 Jan;11(1):40-61
pubmed: 28085223
Cancer Res. 2018 Feb 15;78(4):845-852
pubmed: 29437766
Cancers (Basel). 2019 Apr 05;11(4):
pubmed: 30959764
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Trends Cancer. 2015 Sep;1(1):44-52
pubmed: 28741562
Med Hypotheses. 2016 Feb;87:34-9
pubmed: 26826638
Cancer Causes Control. 2014 Nov;25(11):1531-41
pubmed: 25135616
Front Oncol. 2012 Sep 10;2:115
pubmed: 22973557
BMC Cancer. 2012 May 16;12:178
pubmed: 22591372
Res Pract Thromb Haemost. 2018 Jul 26;2(4):622-629
pubmed: 30349879
J Gastrointest Oncol. 2012 Jun;3(2):105-19
pubmed: 22811878
Clin Cancer Res. 2001 Dec;7(12):4080-5
pubmed: 11751505
Int J Oncol. 2016 Dec;49(6):2206-2216
pubmed: 27779656
Breast Cancer Res Treat. 2015 Dec;154(3):563-71
pubmed: 26573830
Eur J Cancer. 2011 Dec;47(18):2698-705
pubmed: 21788129
Sci Rep. 2017 May 26;7(1):2433
pubmed: 28550299
J Fam Pract. 1996 Apr;42(4):391-9
pubmed: 8627208

Auteurs

Dadasaheb Akolkar (D)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Darshana Patil (D)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Timothy Crook (T)

St. Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, United Kingdom.

Sewanti Limaye (S)

Department of Medical Oncology, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India.

Raymond Page (R)

Department of Biomedical Engineering, Worcester Polytechnic Institute, Worcester, Massachusetts.

Vineet Datta (V)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Revati Patil (R)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Cynthe Sims (C)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Anantbhushan Ranade (A)

Avinash Cancer Clinic, Pune, India.

Pradeep Fulmali (P)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Pooja Fulmali (P)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Navin Srivastava (N)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Pradip Devhare (P)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Sachin Apurwa (S)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Shoeb Patel (S)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Sanket Patil (S)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Archana Adhav (A)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Sushant Pawar (S)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Akshay Ainwale (A)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Rohit Chougule (R)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Madhavi Apastamb (M)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Ajay Srinivasan (A)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Rajan Datar (R)

Department of Research and Innovations, Datar Cancer Genetics Limited, Nasik, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH